Literature DB >> 6437365

Costs and benefits of two doses of fluphenazine.

S R Marder, T Van Putten, J Mintz, J McKenzie, M Lebell, G Faltico, P R May.   

Abstract

The relative costs and benefits of low- and conventional-dose neuroleptic maintenance therapy were evaluated in a double-blind comparison of 5 and 25 mg of fluphenazine decanoate administered every two weeks. Subjects were 50 patients fulfilling DSM-III criteria for schizophrenic disorder who had been successfully maintained with 25 mg or less of fluphenazine decanoate. A one-year survival analysis disclosed that there were no statistically significant differences between the two doses insofar as preventing relapse. Patients receiving the higher dose appeared to feel more uncomfortable, as indicated by higher scores on subscales of the Hopkins Symptom Checklist-90. In addition, patients receiving the higher dose had higher side-effect scores. These findings suggest that a substantial proportion of patients who are presently maintained with 25 mg or less of fluphenazine decanoate every two weeks will do just as well with as little as 5 mg.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6437365     DOI: 10.1001/archpsyc.1983.01790220015002

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  19 in total

Review 1.  Dose response and atypical antipsychotics in schizophrenia.

Authors:  Bruce J Kinon; Jonna Ahl; Virginia L Stauffer; Angela L Hill; Peter F Buckley
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

2.  Tardive dyskinesia: update for the mental health administrator.

Authors:  J E Kalachnik; K M Slaw
Journal:  J Ment Health Adm       Date:  1986

3.  Psychometric properties of the Taiwanese version of the Illness Concept Scale: relation of health beliefs to psychopathology and medication compliance.

Authors:  Yu-Chen Kao; Yia-Ping Liu; Ming-Kuen Chou; Tsung-Hsing Cheng
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2011-03-04       Impact factor: 4.328

Review 4.  Pharmacological treatment of patients with schizophrenia. Past and present problems and potential future therapy.

Authors:  D A Johnson
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

Review 5.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Authors:  Sofia Brissos; Miguel Ruiz Veguilla; David Taylor; Vicent Balanzá-Martinez
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

Review 6.  Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications.

Authors:  S R Marder; J W Hubbard; T Van Putten; K K Midha
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

7.  Low dose maintenance medication for schizophrenia.

Authors:  D A Johnson
Journal:  Br Med J (Clin Res Ed)       Date:  1986-10-25

8.  Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate.

Authors:  S R Marder; E M Hawes; T Van Putten; J W Hubbard; G McKay; J Mintz; P R May; K K Midha
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

9.  Neuroleptic medication and prescription practices with sheltered-care residents: a 12-year perspective.

Authors:  S P Segal; D Cohen; S R Marder
Journal:  Am J Public Health       Date:  1992-06       Impact factor: 9.308

10.  Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I.

Authors:  R Miller
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.